To detect potential impurities by residual melanocytes/melanoma cells and Langerhans cells, the final drug product (ABCB5+ LSCs) was evaluated by immunofluorescence staining for MART-1 (n = 4 batches) and CD1a (n = 3 batches), respectively. This evidence concerns the gene ABCB5 and melanoma.